1. HBW Insight
  2. >>Geography
  3. >>Latin America

Hypera Immediately Offloads Takeda Brands To Concentrate On Brazil

 
• By Tom Gallen

Hypera is offloading a basket of brands it recently acquired from Takeda which are sold primarily in Mexico to São Paulo-based Eurofarma. 

Mexico
• Source: Shutterstock

Brazil remains [Hypera Pharma SA]’s number-one priority with the firm poised to offload a basket of brands sold across other Latin American markets to Eurofarma Laboratorios SA.

With the ink barely dry on its agreement to acquire the brands from Takeda Pharmaceutical Co. Ltd. – as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Latin America

Bayer Consumer Health Expands North America And LATAM Supply Capacity

Bayer is investing $52m in its Lerma, Mexico manufacturing site, which the firm said will enable it to increase production of key OTC brands like Aspirin and Alka-Seltzer from 100m to 140m units by 2030.

Perrigo Q2 Results Down Nearly 11% On Formula Slump Despite Women’s Health Sales Jump On Opill

 
• By Malcolm Spicer

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Opill Launch Delivers For Perrigo While Growing Pains Slow Overall First-Quarter Results

 
• By Malcolm Spicer

Perrigo spares little about Opill’s launch, advertising and outlook in Q1 earnings briefing, but management also makes clear it’s a large firm and some other segments of its global consumer health products business are holding back overall results.

Herbalife's Rising Digital Platform Floats All Boats Other Than Marketing To GLP-1 Patients

 
• By Malcolm Spicer

Direct seller reports Q1 sales up 1% to $1.3bn but net sales off 17.1% from year-ago period to $24.3m. Its distributor ranks jumped so far in 2024, particularly in China, where changes were made in the past year including new company leadership.

More from Geography

Over The Counter: Seizing The Healthy Aging Opportunity, With Prime Fifty’s Max Gowland

 
• By David Ridley

HBW Insight speaks to Prime Fifty founder and managing director Max Gowland about the science behind healthy aging and the opportunity for the consumer health industry.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.